Payment overview · 2025
General Payments
$361.18
19 reported records · 10 companies
Healthcare provider profile · identity verified
Clint Chachere Butler, MD
Allopathic & Osteopathic Physicians|Family Medicine · HAYNESVILLE, LA · NPI 1306876826
Verified facts
What the public records show
CMS Open Payments records show Clint Chachere Butler, MD received $361.18 in general payments during 2025 across 19 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 30.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $110.42 | 30.6% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.92 | 14.1% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $47.78 | 13.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.34 | 10.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $26.66 | 7.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.88 | 5.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.78 | 5.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.58 | 4.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.91 | 4.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.91 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $361.18 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $110.42 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $47.78 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $39.34 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.21 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.21 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 111 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
159 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
111 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
159 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 400 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 375 | 63 |
| Atorvastatin Calcium | Atorvastatin Calcium | 358 | 52 |
| Losartan Potassium | Losartan Potassium | 351 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 315 | 47 |
| Potassium Chloride | Potassium Chloride | 309 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 300 | 52 |
| Alprazolam | Alprazolam | 299 | 42 |
| Gabapentin | Gabapentin | 238 | 41 |
| Furosemide | Furosemide | 200 | 33 |
| Meloxicam | Meloxicam | 196 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 185 | 26 |
| Prednisone | Prednisone | 184 | 93 |
| Trazodone Hcl | Trazodone Hcl | 181 | 26 |
| Omeprazole | Omeprazole | 173 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 160 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 160 | 24 |
| Eliquis | Apixaban | 159 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 26 |
| Lisinopril | Lisinopril | 137 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 134 | 22 |
| Celecoxib | Celecoxib | 133 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 25 |
| Tramadol Hcl | Tramadol Hcl | 132 | 40 |
| Montelukast Sodium | Montelukast Sodium | 130 | 22 |
| Donepezil Hcl | Donepezil Hcl | 125 | 20 |
| Clonazepam | Clonazepam | 121 | 19 |
| Allopurinol | Allopurinol | 116 | 19 |
| Jardiance | Empagliflozin | 111 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 106 | 74 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 17 |
| Simvastatin | Simvastatin | 101 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 12 |
| Metformin Hcl | Metformin Hcl | 98 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 98 | 26 |
| Linzess | Linaclotide | 93 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 30 |
| Temazepam | Temazepam | 91 | 12 |
| Bumetanide | Bumetanide | 89 | 12 |
| Ozempic | Semaglutide | 87 | 14 |
| Torsemide | Torsemide | 87 | 17 |
| Azithromycin | Azithromycin | 85 | 66 |
| Cefprozil | Cefprozil | 85 | 61 |
| Famotidine | Famotidine | 83 | 17 |
| Meclizine Hcl | Meclizine Hcl | 79 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 79 | 12 |
| Sucralfate | Sucralfate | 79 | 15 |
| Atenolol | Atenolol | 78 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 76 | 11 |
| Pregabalin | Pregabalin | 76 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 74 | 52 |
| Fluconazole | Fluconazole | 73 | 41 |
| Glimepiride | Glimepiride | 71 | 12 |
| Carvedilol | Carvedilol | 70 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | suppressed |
| Januvia | Sitagliptin Phosphate | 60 | suppressed |
| Xarelto | Rivaroxaban | 58 | suppressed |
| Memantine Hcl | Memantine Hcl | 57 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 57 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 55 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 54 | suppressed |
| Lorazepam | Lorazepam | 54 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 54 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 53 | 13 |
| Levofloxacin | Levofloxacin | 53 | 33 |
| Tiadylt Er | Diltiazem Hcl | 52 | suppressed |
| Entresto | Sacubitril/Valsartan | 50 | suppressed |
| Ezetimibe | Ezetimibe | 49 | suppressed |
| Mupirocin | Mupirocin | 49 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | suppressed |
| Methylprednisolone | Methylprednisolone | 47 | 38 |
| Spironolactone | Spironolactone | 47 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 46 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 45 | suppressed |
| Ondansetron Odt | Ondansetron | 45 | 15 |
| Diazepam | Diazepam | 44 | suppressed |
| Methocarbamol | Methocarbamol | 44 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | suppressed |
| Finasteride | Finasteride | 43 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 42 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 12 |
| Alendronate Sodium | Alendronate Sodium | 41 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 41 | 11 |
| Baclofen | Baclofen | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 20 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 39 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 38 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 37 | suppressed |
| Irbesartan | Irbesartan | 35 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Latanoprost | Latanoprost | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 22 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 25 | 18 |
| Estradiol | Estradiol | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 17 |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Ofloxacin | Ofloxacin | 23 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Nabumetone | Nabumetone | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | 15 |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Felodipine Er | Felodipine | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Digoxin | Digoxin | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Trandolapril | Trandolapril | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $361.18 · 19 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, Auvelity, CAPLYTA, COBENFY, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, REXULTI, The Cologuard Plus Collection Kit, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error